Argoff CE. Topical agents for the treatment of chronic pain. Curr Pain Headache Rep. 2006;10(1):11–9.
Theis JG, Koren G. Camphorated oil; still endangering the lives of Canadian children. CMAJ. 1995;152(11):1821–4.
Watson CPN. Topical capsaicin as an adjuvant analgesic. J Pain Symptom Manage. 1994;9:425–33.
Rains C, Bryson HM. Topical capsaicin: a review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy, and osteoarthritis. Drugs Aging. 1995;7:317–28.
Fuchs PN, Papagallo M, Meyer RA. Topical EMLA pre-treatment fails to decrease the pain induced by 1% topical capsaicin. Pain. 1999;80:637–42.
Yanigidate F, Strichartz GR. Local anesthetics. Handb Exp Pharmacol. 2007;177:95–127.
Hollman MW, Durieux ME. Local anesthetics and the inflammatory response. Anesthesiology. 2000;93:858–75.
Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol. 2003;43(2):111–7.
Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs-differences and similarities. N Engl J Med. 1991;324:1716–25.
http://nbcsports.msnbc.com/id/19144600/. Last accessed 2/5/2013.
Nair B, Taylor-Gjevre R. A review of topical diclofenac use in musculoskeletal disease. Pharmaceuticals. 2010;3:1892–908.
Kastrup EK, editor. Drug facts and comparisons. St. Louis: Wolters Kluwer Health; 2013. p. 3147–9.
McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol. 2000;49(6):574–9.
Gerner P, Mujtaba M, Sinnott CJ, Wang GK. Amitriptyline versus bupivacaine in rat sciatic nerve blockade. Anesthesiology. 2001;94:661–7.
Khan MA, Gerner P, Wang GK. Amitriptyline for prolonged cutaneous analgesia in the rat. Anesthesiology. 2002;96:109–16.
Long TD, Cathers TA, Twillman R, O’Donnell T, Garrigues N. Morphine-infused silver sulfadiazine cream for burn analgesia: a pilot study. J Burn Care Rehabil. 2001;22:118–23.
Cerchietti LC, Navigante AH, Bonomi MR, Zaderajko MA, Menendez PR, Pogany CE, Roth BM. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer. 2002;95(10):2230–6.
Watterson G, Howard R, Goldman A. Peripheral opiates in inflammatory pain. Arch Dis Child. 2004;89:679–81.
Capriotti K, Capriotti JA. Dimethyl sulfoxide: history chemistry, and clinical utility in dermatology. J Clin Aesthet Dermatol. 2012;5(9):24–6.
Meyer T, Martin E, Prielipp R. The largest healthcare associated fungal outbreak in the U.S. APSF Newslett. 2013;28(1):4–7.
Ness TJ, Jones L, Smith H. Use of compounded topical analgesics-results of an internet survey. Reg Anesth Pain Med. 2002;27:309–12.
Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden 3rd JD, Kugler JW, Hoff KL, Reddy PS, Rowland Jr KM, Riepl M, Christensen B, Loprinzi CL. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011;19(6):833–41.
Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology. 2005;103(1):140–6.
Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. J Pain. 2005;6(10):644–9.
Quan D, Wellish M, Gilden DH. Topical ketamine treatment of post-herpetic neuralgia. Neurology. 2003;60:1391–2.